DYNHIGH SIGNALFINANCIAL10-K

DYN substantially increased its cash position and assets while meaningfully expanding R&D spending, but operating losses grew proportionally larger.

The dramatic increase in total assets and stockholders' equity suggests a significant capital raise that provided substantial funding for expanded operations. However, the company's revised timeline language indicates commercialization has been pushed back to 2027 from the previous "couple of years" guidance, signaling potential development challenges or a more conservative outlook.

Comparing 2026-03-02 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

DYN's balance sheet strengthened considerably with total assets growing from $691.2M to $1.2B and stockholders' equity expanding to $972.1M, indicating a successful capital raise. The company meaningfully expanded R&D spending by 41.6% to $398.3M, but this translated to proportionally larger operating losses and cash burn. While the company now has a stronger financial foundation to fund operations, the increased burn rate and extended commercialization timeline suggest investors should expect continued significant cash consumption through 2027.

FINANCIAL STATEMENT CHANGES
Total Assets
Balance Sheet
+71.7%
$691.2M$1.2B

Asset base grew 71.7% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+70.9%
$659.3M$1.1B

Current assets grew 70.9% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+54.3%
$629.8M$972.1M

Equity base grew 54.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
+41.6%
$281.4M$398.3M

R&D investment increased 41.6% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-40.6%
-$317.4M-$446.2M

Net income declined 40.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-37.9%
-$292.4M-$403.2M

Operating cash flow fell 37.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-36.1%
-$343.9M-$468.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+19.8%
$42.3M$50.6M

Current liabilities rose 19.8% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-27
ADDED
We do not expect to have a product candidate ready for commercialization at least until 2027, if ever.
Overview We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
Our proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS.
The FORCE platform utilizes an antigen-binding fragment antibody, or Fab, targeting TfR1 conjugated to a payload that we rationally design to target the genetic basis of the disease we are seeking to treat.
In addition, we plan to expand our portfolio through development efforts focused on diseases involving the CNS, rare skeletal muscle diseases, and cardiac and metabolic muscle diseases, including some with larger patient populations.
+7 more — sign up free →
REMOVED
As a result, it will be at least a couple of years before we commercialize a product candidate, if ever.
Overview We are a clinical-stage neuromuscular disease company focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases.
Leveraging the modularity of our FORCE platform, we are developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS.
Our proprietary FORCE platform therapeutics consist of a payload that we rationally design to target the genetic basis of the disease we are seeking to treat, a linker and an antigen-binding fragment, or Fab, that we attach to the payload using the linker.
In addition, we plan to expand our portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases, including some with larger patient populations, and diseases involving the CNS.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →